STOCK TITAN
  1. Home
  2. Sec-filings
  3. HAE
  4. [8-K] HAEMONETICS CORP Reports Material Event

Haemonetics (NYSE: HAE) signs CSL Plasma pact with 2027 impact update planned

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Haemonetics Corporation entered into a non-exclusive supply agreement with CSL Plasma Inc. under which CSL may use Haemonetics’ NexSys PCS® devices with Persona® PLUS technology and purchase related disposables for U.S. plasma collection centers. The agreement does not include minimum purchase commitments, and Haemonetics currently expects CSL to transition only a portion of its U.S. centers, with the scope and timing of that transition still undetermined. Because of this uncertainty, Haemonetics is not revising its fiscal 2027 guidance at this time and plans to discuss the anticipated financial impact of the agreement in conjunction with its second fiscal quarter earnings call in November 2026.

Positive

  • None.

Negative

  • None.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Agreement date August 14, 2026 Date Haemonetics entered into the supply agreement with CSL Plasma
Guidance period Fiscal 2027 Period for which Haemonetics is not updating previously issued guidance
Planned impact update timing November 2026 Second fiscal quarter earnings call when Haemonetics expects to discuss anticipated impact
Report date August 18, 2026 Date Haemonetics signed the current report through its President and CEO
Regulation FD regulatory
"Item 7.01 Regulation FD Disclosure On August 14, 2026"
Regulation FD is a rule that prevents company insiders, like executives, from sharing important information with some people before others get it. It matters because it helps ensure all investors have equal access to key news, making the stock market fairer and reducing chances of insider trading.
non-exclusive supply agreement financial
"The supply agreement is non-exclusive and does not contain minimum"
minimum purchase commitments financial
"The supply agreement is non-exclusive and does not contain minimum purchase commitments"
forward-looking statements regulatory
"Cautionary Note Regarding Forward-Looking Statements This on contains forward-looking statements"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
fiscal 2027 guidance financial
"the Company is not updating its previously issued fiscal 2027 guidance at this time"

FAQ

What agreement did Haemonetics (HAE) announce with CSL Plasma?
Haemonetics announced a non-exclusive supply agreement with CSL Plasma, allowing CSL to use NexSys PCS® devices with Persona® PLUS technology and related disposables in its U.S. plasma collection centers.

Are there minimum purchase commitments in the Haemonetics (HAE) agreement with CSL Plasma?
No. The supply agreement between Haemonetics and CSL Plasma does not contain minimum purchase commitments, so CSL’s actual purchase volume will depend on its future utilization decisions.

How will the CSL Plasma agreement affect Haemonetics’ (HAE) fiscal 2027 guidance?
Haemonetics is not updating its fiscal 2027 guidance in connection with the CSL Plasma agreement, citing uncertainty around the scope and timing of CSL’s transition to Haemonetics’ devices.

When will Haemonetics (HAE) discuss the financial impact of the CSL agreement?
Haemonetics expects to provide an update on the anticipated fiscal 2027 financial impact of the CSL Plasma agreement during its second fiscal quarter earnings call in November 2026.

Is the CSL Plasma supply agreement exclusive for Haemonetics (HAE)?
No. Haemonetics describes the CSL Plasma supply agreement as non-exclusive, meaning CSL may also use products from other suppliers in its plasma collection centers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0000313143false00003131432026-08-182026-08-18

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 18, 2026

HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
Massachusetts001-1404104-2882273
(State or other jurisdiction
of incorporation)
(Commission File Number)
(I.R.S. Employer
Identification No.)

125 Summer Street
Boston, MA 02110
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781-848-7100
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $.01 par value per shareHAENew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 7.01  Regulation FD Disclosure
On August 14, 2026, Haemonetics Corporation (the “Company”) entered into a supply agreement with CSL Plasma Inc. (“CSL”) pursuant to which CSL may utilize the Company’s NexSys PCS® devices with Persona® PLUS technology and purchase related disposables in the United States. The supply agreement is non-exclusive and does not contain minimum purchase commitments.
Haemonetics anticipates CSL to transition a portion of its U.S. plasma collection centers to the Company’s devices and disposables, but the scope and timing of implementation have not yet been determined. Accordingly, the Company is not updating its previously issued fiscal 2027 guidance at this time. The Company expects to provide an update regarding the anticipated impact of the agreement on its fiscal 2027 financial results in connection with its second fiscal quarter earnings call in November 2026.
The foregoing information in this Item 7.01 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
Cautionary Note Regarding Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements about the Company’s non-exclusive supply agreement with CSL, including, but not limited to, statements related to the expected utilization of Company products at CSL centers and the Company’s anticipated timing for updates relating to the impact of the agreement on the Company’s fiscal 2027 financial results. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties, which include, without limitation, customer demand and adoption of the Company’s products, the timing and volume of any purchases by CSL under the agreement, the Company’s ability to manufacture and supply its products, and other factors described in the Company’s filings with the Securities and Exchange Commission. Investors should consult the Company’s filings with the Securities and Exchange Commission (including the Company’s reports on Forms 10-K, 10-Q and 8-K) for information about additional risks and uncertainties that could cause the Company’s actual results to differ materially from those described in this Current Report on Form 8-K. The Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form 8-K as a result of new information, future events or changes in its expectations.



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HAEMONETICS CORPORATION
August 18, 2026By:/s/ Christopher A. Simon
Name:Christopher A. Simon
Title:President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents